Gaps in Care Technical Specifications and PCP Billing Guide HEDIS 2019



Working together to enhance the Quality of Care provided to our Members



Table of Contents

Disclaimer/What is HEDIS

Annual HEDIS Timeline

Tips and Best Practice/HIPAA

The Importance of Documentation

Quality Measures

- **AAP** Avoidance of Antibiotic Treatment in Adults with Acute Bronchitis
- AAP Adults'Access to Preventive/Ambulatory Health Services
- ABA Adult BMI Assessment
- ADD Follow-Up Care for Children Prescribed ADHD Medication
- ADV Annual Dental Visit
- AMM Antidepressant Medication Management
- AMR Asthma Medication Ratio
- **ART** Disease-Modifying Anti-Rheumatic Drug Therapy for Rheumatoid Arthritis
- AWC Adolescent Well-Care Visits
- BCS Breast Cancer Screening
- CAP Children and Adolescents' Access to Primary Care Practitioners
- **CBP** Controlling High Blood Pressure
- **CCS** Cervical Cancer Screening
- CDC Comprehensive Diabetes Care
 - CDC BP Blood Pressure Less Than 140/90 CDC DRE Dilated Retinal Eye Exam
 - CDC HcA1c HbA1c testing and resuts
- CDC Neph Medical Attention for Nephropathy
- CHL Chlamydia Screening in Women
- CIS Childhood Immunization Status
- **COA** Care for Older Adults
- **COL** Colorectal Cancer Screening
- CWP Appropriate Testing for Children with Pharyngitis
- DAE Use of High-Risk Medications in the Elderly
- DDE Potentially Harmful Drug-Disease Interactions in the Elderly
- FUH Follow-up After Hospitalization for Mental Illness
- IMA Immunizations for Adolescents
- LBP Use if Imaging Studies for Low Back Pain
- LSC Lead Screening in Children
- MMA Medication Management for People with Asthma
- OMW Osteoporosis Management in Women Who Had a Fracture
- **PBH** Persistence of Beta-Blocker Treatment After a Heart Attack
- PCE Pharmacotherapy Management of COPD Exacerbation
- PPC Prenatal and Postpartum Care
- PSA Non-Recommended PSA-Based Screening in Older Men
- SAA Adherence to Antipsychotic Medications for Individuals with Schizophrenia
- SPC Statin Therapy for Patients with Cardiovascular Disease
- SPD Statin Therapy for Patients with Diabetes
- SSD Diabetes Screening for People with Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic
- URI Appropriate Treatment for Children with Upper Respiratory Infection
- W15 Well-Child Visits in the First 15 Months of Life
- W34 Well-Child Visits in the Third, Fourth, Fifth & Sixth Year of Life
- WCC Weight Assessment & Counseling for Nutrition & Physical Activity for Children and Adolescents

Disclaimer

This material serves as a tool to assist providers, their clinical team, and billing staff with information to improve HEDIS performance.

HEDIS 2019 Volume 2 Technical Specifications for Health Plans was used to generate this Provider Billing Guide. The Technical Specifications were current at the time of publication (November 2018).

HEDIS indicators have been designed by NCQA to standardize performance measurement and do not necessarily represent the ideal standard of care.

ICD-9 codes have been removed from this guide. For measures with a look back period further than Oct. 2016, the ICD-9 codes used with claims during that time frame will continue to be pulled into the HEDIS software.

Information contained in this report is based on claims data only.

What is HEDIS?


HEDIS is a registered trademark of the National Quality Committee for Quality Assurance (NCOA)

<u>H</u>ealthcare <u>Effectiveness</u> <u>D</u>ata and <u>I</u>nformation <u>S</u>et (HEDIS)



NCQA defines HEDIS as "a set of standardized performance measures designed to ensure that purchasers and consumers have the information they need to reliably compare the performance of health care plans." HEDIS is a registered trademark of the National Committee for Quality Assurance HEDIS is a performance measurement tool that is coordinated and administered by NCQA and used by the Centers for Medicare & Medicaid Services (CMS) for monitoring the performance of managed care organizations Results from HEDIS data collection serve as measurements for quality improvement processes, educational initiatives, and preventive care programs All managed care companies who are NCQA accredited perform HEDIS reviews the same time each year HEDIS 2019 consists of 92 measures across six domains of care that address important health issues HEDIS is a retrospective review of services and performance of care from the prior calendar year There are two types of HEDIS data reffered to in this guide: Administrative data - comes from submitted claims and encounters Hybrid data - comes from chart collection/review

Annual HEDIS Timeline



Data collection methods include: fax, mail, onsite visits for larger requests, and remote electronic medical record (EMR) system access if available

Medical record fax requests will include a member list identifying their assigned measure(s) and the minimum necessary information needed sent to the health plan

Due to the shortened data collection timeframe, a turnaround time of 3-5 days is appreciated

For on-site chart collections, the office will be contacted to schedule a time the abstractor can come to the office for chart review. A list of members charts being reviewed will be provided ahead of time

Tips and Best Practices

General tips and information that can be applied to most HEDIS measures:

1. Use your member roster to contact patients who are due for an exam or are new to your practice

2. Take advantage of this guide, coding information, and the on-line resources that can assist the practice with HEDIS measure understanding, compliance, and requirements

3. Use your Gaps in Care member list to outreach to patients in need of services/procedures.

4. You can provide evidence of completed HEDIS services and attach the supporting chart documentation by contacting the Quality Management department.

5. Schedule the members' next well-visit at the end of the current appointment

6. Assign a staff member at the office knowledgeable about HEDIS to perform internal reviews and serve as a point of contact with plans and their respective Quality Management staff.

7. Set up your Electronic Health Records (EHRs) so that the HEDIS alerts and flags to alert office personnel of patients in need of HEDIS services.

HIPAA

Under the Health Information Portability and Accountability Act (HIPAA) Privacy Rule, data collection for HEDIS is permitted, and the release of this information requires no special patient consent or authorization. Please be assured our members' personal health information is maintained in accordance with all federal and state laws. HEDIS results are reported collectively without individual identifiers or outcomes. All of the health plans' contracted providers' records are protected by these laws.

1. HEDIS data collection and release of information is permitted under HIPAA since the disclosure is part of quality assessment and improvement activities

2. The records you provide us during this process helps us to validate the quality of care our members received

	Importance of Documentation
Principl	es of the medical record and proper documentation:
	1. Enable physician and other healthcare professionals to evaluate a patient's healthcare needs and assess the efficacy of the treatment plan
	2. Serves as the legal document to verify the care rendered and date of service
	3. Ensure date of care rendered is present and all documents are legible
	4. Serves as communication tool among providers and other healthcare professionals involved in the patient's care for improved continuity of care
	5. Facilitates timely claim adjudication and payment
	7. Appropriately documented medical record can reduce many of the 'hassles' associated with claims processing and HEDIS chart requests
	8. ICD-10 and CPT codes reported on billing statements should be supported by the documentation in the medical record
	n reasons members with PCP visits continue to need recommended /procedures:
Scivices	
	1. Missing or lack of all required documentation components
	2. Service provided without claim/encounter data submitted
	3. Lack of referral to obtain the recommended service (i.e. diabetic member eye exam to check for retinopathy)
	4. Service provided but outside of the required time frame or anchor date (i.e. Lead screening performed after age 2)
	5. Incomplete services (i.e.No documentation of anticipatory guidnace during a well visit for the adolescent well child measure)
	6. Failure to document or code exclusion criteria for a measure
	ok for the 'Common Chart Deficiencies and Tips' sections for guidance th some of the more challenging HEDIS measures

AAB Avoidance of Ar	AAB Avoidance of Antibiotic Treatment in Adults With Acute				
Bronchitis					
Measure Definition:					
The percentage of ad	ults 18–64 years of age with a diagnosis of acute bronchitis who				
were not dispensed a	n antibiotic prescription.				
*Inverted N	Aeasure: Numerator identifies members prescribed an antibiotic;				
considered	non-compliant for the intent of this measure.				
	Billing Reference				
Description	ICD-10 CM				
Acute Bronchitis	J20.3-J20.9				
Measure Exclusion Crite	eria:				
The member is exclud	led from the measure if he/she has a diagnosis of pharyngitis or				
another competing d	iagnosis 30 days prior to or 7 days after the acute bronchitis				
diagnosis. The list of	competing diagnosis includes all types of infections that would				
require treatment wi	require treatment with an antibiotic.				
Any member with a comorbid condition diagnosis in the 12 months prior to the acute					
bronchitis diagnosis would be excluded. The comorbid diagnoses for this measure					
include: HIV, malignant neoplasms, emphysema, COPD, cystic fibrosis, tuberculosis, and					
other lung diseases.	other lung diseases.				
HEDIS [®] stands for Healthcare Effectiveness Data (NCQA).	and Information Set and is a registered trademark of the National Committee for Quality Assurance				

AAP Adult	s' Access to Preventive/Amb	ulatory Health Services		
	ion: ers 20 year and older who had an ambulate rement year.	ory or preventive care visit during the		
visit a	Common Chart Deficiencie ch adult Medicaid or Medicare member sh annually. lize your Gaps in Care report to outreach m	ould have a routine outpatient		
	Billing Referen	ce		
Description	C	РТ		
	99201-99205, 99211-99215, 99241-99245, 99341-99345, 99347-99350, 99381- 99387, 99391-99397, 99401-99404, 99411-99412, 99429			
	HCPCS	UBREV		
Ambulatory Visits	G0402, G0438, G0439, G0463, T1015 051X, 052X, 0982, 0983			
	ICD 10			
	Z00.00, Z00.01, Z00.121, Z00.129, Z00.3, Z00.5, Z00.8, Z02.0-Z02.6, Z02.71, Z02.79, Z02.81-Z02.83, Z02.89, Z02.9, Z76.1, Z76.2			
	C	РТ		
Other Ambulatory Visits	92002, 92004, 92012, 92014, 99304-99310, 99315, 99316, 99318, 99324-99328, 99334-99337			
	UBREV	0524, 0525		
Any of the above ambulatory visits with or without a telehealth modifier:				
	Telehealth CPT Modifier:	95, GT		
Online Assessments	СРТ	98969, 99444		
Telephone Visits	СРТ	98966-98968, 99441-99443		
HEDIS [®] stands for Healtho (NCQA).	care Effectiveness Data and Information Set and is a registered tra	ademark of the National Committee for Quality Assurance		

ABA Adult BMI Assessment

Measure Definition:

The percentage of members 18–74 years of age who had an outpatient visit and whose body mass index (BMI) was documented in 2017 or 2018.

For members 20 years of age or older on the date of service: weight and BMI in 2017 or 2018 must be documented from the same data source.

For members younger than 20 years of age on the date of service: BMI percentile must be documented in 2017 or 2018. Chart documentation should include height, weight and BMI percentile (as a value e.g. 85th or plotted on a growth chart). Documentation of ranges or thresholds do not meet criteria for this indicator.

Common Chart Deficiencies and Tips:

1. Common deficiency: Height and weight documented but no documentation of the BMI

2. ICD-10 Z68 codes can be used to make a member compliant without chart review.

3. ICD-9 codes should not be used for this service

	Billing Reference					
Description	Description ICD-10					
ВМІ	3MI Z68.1, Z68.20-Z68.29, Z68.30-Z68.39, Z68.41-Z68.45					
BMI Percentile	Z68.51-Z68.54					
Measure Exclu	ision Criteria:					
-	on for this measure is pregnancy. Exclusionary evidence in the medical record must dicating a diagnosis of pregnancy. The diagnosis must have occurred during the 2017					

HEDIS[®] stands for Healthcare Effectiveness Data and Information Set and is a registered trademark of the National Committee for Quality Assurance (NCQA).

ADD Follow-Up Care for Children Prescribed ADHD Medication

Measure Definition:

С

m

The percentage of children newly prescribed attention-deficit/hyperactivity disorder (ADHD) medication who had at least three follow-up care visits within a 10-month period, one of which was within 30 days of when the first ADHD medication was dispensed. Two rates are reported.

Initiation Phase. The percentage of members 6–12 years of age with an ambulatory prescription dispensed for ADHD medication, who had one follow-up visit with practitioner with prescribing authority during the 30-day Initiation Phase.

Continuation and Maintenance (C&M) Phase. The percentage of members 6–12 years of age with an ambulatory prescription dispensed for ADHD medication, whom remained on the medication for at least 210 days and who, in addition to the visit in the Initiation Phase, had at least two follow-up visits with a practitioner within 270 days (9 months) after the Initiation Phase ended.

Common Chart Deficiencies and Tips

1. No refills until the initial follow-up visit is complete

2. Conduct initial follow-up visit 2-3 weeks after member starts medication therapy

3. Schedule additional 2 visits within 9 months of medication at the time of the initial follow-up visit

4. If member cancels an appointment, reschedule appointment right away

Billing Reference					
	ADHD Medicatio	ns			
Description Prescriptions					
CNS stimulants	Amphetamine- dextroamphetamine	Lisdexamfetamine			
	Dexmethylphenidate	Methamphetamine			
	Dextroamphetamine	Methylphenidate			
Alpha-2 receptor agonists	Clonidine	Guanfacine			
Viscellaneous ADHD	Atomousting				
medications	Atomoxetine				

ADD continued						
Codes to Ide	ntify Fol	low-Up \	/isits in t	the Initia	tion Pha	se
	BH S	tand Alon	e Visit Coo	les		
СРТ			HCPCS		U	B Revenue
98960-98962, 99078, 99201- 99211-99215, 99241-99245, 99345, 99347-99350, 99381-	G0155, G0176, G0177, G0409, G0463, H0002, H0004, H0031, H0034- H0037, H0039, H0040, H2000, H2010-H2011, H2013- H2020, M0064, T1015		0519-0 0900, (0513, 0515-0517, 0523, 0526-0529, 0902-0904, 0911, 0917, 0919, 0982, 0983		
Observation V	isit		CPT Code	s	9	9217-99220
li	ntensive C)P Encoun	ter/Partia	l Hospital		
НСР	CS				UBI	REV
	G0410-0411, H0035, H2001, H2012, S0201, S9480, S9484- 9485 9485				912, 913	
CPT POS						
90847, 90849, 90853, 90875, 9	90791, 90792, 90832-90834, 90836-90840, 90845, 90847, 90849, 90853, 90875, 90876, 99221-99223, 99231-99233, 99238, 99239, 99251-99255					
Codes t	o Identif	y Follow	-Up Visit	s - C&M	Phase	
All th	e codes lis	ted above	for the In	itiation Ph	lase	
PLUS one fo	ollow-up v	isit can be	telephoni		&M Phase	
-	Description CPT					
Telephone Visits	98966-98968, 99441-99443					
	Telehealth Modifier95, GTTelehealth POS2					2
Measure Exclusion Crite	eria:					
Exclusion				CD-10 CN	Λ	
Diagnosis of Narcolepsy						
HEDIS® stands for Healthcare Effectiveness Data and Information Set and is a registered trademark of the National Committee for Quality Assurance (NCQA).						

ADV Annual	Dental Visit			
measurer	: entage of members 2–20 years of age who had at least one dental visit in the nent year. This measure applies only if dental care is a covered benefit in the ion's Medicaid contract.			
Tips: 1. Educate parents/guardians about the importance of dental care starting when the child is young. 2. Ask when the last dental appointment was during every well visit				
	Billing Reference			
	Description			
Dental Visits All codes have been removed from this measure. Any claim with a dental practitioner during the measurement year meets criteria.				
HEDIS [®] stands for Healthcare (NCQA).	Effectiveness Data and Information Set and is a registered trademark of the National Committee for Quality Assurance			

AMM Antidepressant Medication Management

Measure Definition:

The percentage of members 18 years of age and older who were treated with antidepressant medication, had a diagnosis of major depression and who remained on an antidepressant medication treatment. Two rates are reported.

Effective Acute Phase Treatment. The percentage of members who remained on an antidepressant medication for at least 84 days (12 weeks).

Effective Continuation Phase Treatment. The percentage of members who remained on an antidepressant medication for at least 180 days (6 months).

Common Chart Deficiencies and Tips

1. Talk to patient about depression and their treatment plan. The stigma associated with a diagnosis of depression that may result in a patient declining medication or stopping the medication after they start

2. Explain what they can expect when starting the medication and how long it may take before they feel the effect

3. Stress the importance of staying on the medication. Patient should call if having problems with the medication and never stop the medication without consulting you

4. Schedule follow-up visits before patient leaves office and stress the need for follow-up visits.

Bil	ling	Refe	ren	ce
	B			

Description	ICD-10 CM				
Major Depression		F32.0-F32.4, F32.9,	F33.0-F33.3, F33.41, F	F33.0-F33.3, F33.41, F33.9	
Description		M	edication		
Miscellaneous Antidepressants	Bupropion	• Bupropion • Vilazodone			
Monoamine Oxidase Inhibitors	• Isocarboxazid	Phenelzine	• Selegiline	• Tranylcypromine	
Phenylpiperazine Antidepressants	Nefazodone	• Trazadone			
Psychotherapeutic	Amitriptyline-chlordiazepoxide		Amitriptyline-perphenazine		
Comb	• Fluoxetine-olanzap	pine	-		
SNRI Antidepressants	Desvenlafaxine	Duloxetine	• Levomilnacipran	• Venlafaxine	
	Citalopram	• Escitalopram	Fluoxetine	• Fluvoxamine	
SSRI Antidepressants	Paroxetine	Sertraline			
Tetracyclic Antidepressants	Maprotiline	• Mirtazapine			
Tatua avalia	Amitriptyline	Clomipramine	• Doxepin (>6mg)	Nortriptyline	
Tetracyclic Antidepressants	Amoxapine	Desipramine	Imipramine	Protriptyline	
Annuchiessants	• Trimipramine				

HEDIS® stands for Healthcare Effectiveness Data and Information Set and is a registered trademark of the National Committee for Quality Assurance (NCQA).

AMR Asthma Medication Ratio Measure Definition: The percentage of members 5-64 years of age who were identified as having persistent asthma and had a ratio of controller medications to total asthma medications of 0.50 or greater during the year. **Common Chart Deficiencies and Tips:** 1. Perform a thorough review of medications at each visit to ensure that prescribed controller medication is being utilized 2. Provide medication compliance education **Billing Reference** Description **ICD-10 CM** J45.20-J45.22, J45.30-J45.32, J45.40-J45.42, J45.50-J45.52, J45.901-Asthma J45.902, J45.909, J45.990-J45.991, J45.998 Members with any of these diagnoses, anytime in their history are excluded from this measure: Acute Respiratory Failure, Chronic Respiratory Conditions Due to Fumes/Vapors, COPD, Cystic Fibrosis, Emphysema, Obstructive Chronic Bronchitis, or Other Emphysema Also excluded are any members who had no asthma medications (controller or reliever) dispensed during the measurement year. HEDIS® stands for Healthcare Effectiveness Data and Information Set and is a registered trademark of the National Committee for Quality Assurance (NCQA).

ART Disease-Modifying Anti-Rheumatic Drug Therapy for Rheumatoid Arthritis

Measure Definition:

The percentage of members 18 years of age and older who were diagnosed with rheumatoid arthritis and who were dispensed at least one ambulatory prescription for a disease-modifying anti-rheumatic drug (DMARD) during the measurement year.

	1 1 0 0		
	Billin	g Reference	
Description		ICD-10 CM	
Rheumatoid Arthritis		M05.00-M06.9	
	DMAR	D Medications	
Description	Pre	scriptions	HCPCS J Codes
5-Aminosalicylates	Sulfasalazine		
Alkylating agents	Cyclophosphamide		
Aminoquinolines	Hydroxychloroquine		
Anti-rheumatics	Auranofin Leflunomide	Methotrexate Penicillamine	J9250, J9260
Immunomodulators	Abatacept Adalimumab Anakinra Certolizumab Certolizumab pegol	Etanercept Golimumab Infliximab Rituximab Tocilizumab	J0129, J0135, J0717, J1438, J1602, J1745, J3262, J9310
Immunosuppressive agents	Azathioprine Cyclosporine	Mycophenolate	J7502, J7515, J7516, J7517, J7518
Janus kinase (JAK) Inhibitor	Tofacitinib		
Tetracyclines	Minocycline		
Measure Exclusion C	riteria:		

A diagnosis of HIV any time during the member's history through December 31 of the measurement year OR a diagnosis of pregnancy any time during the measurement year.

Codes to Identify Exclusions				
Description	ICD-10 CM			
ніх	B20, Z21			
HIV Type 2	B97.35			
Pregnancy	O00.0-O9A53, Z03.71-Z36			
Other Exclusions				

Exclude from Medicare reporting members age 66 and older as of 12/31 of the measurement year who were enrolled in an Institutional SNP or living long-term in an institution any time during the measurement year.

Exclude members age 66 to 80 as of 12/31 of the measurement year with BOTH advanced illness and frailty: a claim for an advanced illness condition from the measurement year or the year prior and a claim for frailty in the measurement year.

Exclude members age 81 and older as of 12/31 of the measurement year who had at least one frailty claim.

HEDIS® stands for Healthcare Effectiveness Data and Information Set and is a registered trademark of the National Committee for Quality Assurance (NCQA).

	AWC	Adolescent	Well-Care	Visits
--	-----	-------------------	-----------	--------

Measure Definition:

The percentage of enrolled members 12–21 years of age who had at least one comprehensive wellcare visit with a PCP or an OB/GYN practitioner during the measurement year.

The comprehensive well care must visit include evidence of all of the following:

• Health history - Health history is an assessment of the member's history of disease or illness. Health history can include, but is not limited to, past illness (or lack of illness), surgery or hospitalization (or lack of surgery or hospitalization) and family health history.

• **Physical developemnt history** - Physical developmental history includes developmental milestones and assessment of whether the adolescent is developing skills to become a healthy adult.

• **Mental development history** - Mental developmental history includes developmental milestones and assessment of whether the adolescent is developing skills to become a healthy adult.

Physical exam

• Health education/anticipatory guidance - Health education/anticipatory guidance is given by the health care provider to the member and/or parents or guardians in anticipation of emerging issues that a member and family may face.

Common Chart Deficiencies and Tips:

- 1. Missing or undocumented anticipatory guidance
- 2. Sick visit in calendar year without well-child visit turn a sick visit into a well-child visit
- 3. Schedule next visit at end of each appointment

Examples of documentation that **DOES NOT** meet criteria:

• Health history - notation of allergies or medications or immunization status alone does not meet. If all three are documented this does meet criteria

• **Physical development history** - notation of "appropraite for age" without specific mention of development or "well-developed/nourished appearing" does not meet criteria

• Mental development history - notation of "appropriately responsive for age", "neurological exam" or "well-developed" does not meet criteria

• Physical exam - viatl signs alone or a visit to OB/GYN for OB/GYN topics only do not meet criteria

• Health Education/Anticipatory Guidance - information regarding medications or immunizations or their side effects do not meet criteria

Billing Reference						
Description CPT HCPCS ICD-10 CM						
Office Visit	99383-99385, 99393- 99395	G0438, G0439	Z00.00-Z00.129, Z00.5, Z00.8, Z02.0-Z02.9			

HEDIS® stands for Healthcare Effectiveness Data and Information Set and is a registered trademark of the National Committee for Quality Assurance (NCQA).

for breast cancer from C											
	Jctober 2016 th		The percentage of women who are 52–74 years of age in 2018 and had a mammogram to screen for breast cancer from October 2016 through December 31, 2018.								
Common Chart Deficiencies and Tips: 1. Educate women regarding the benefit of early detection of breast cancer through routine mammograms. 2. Assist with scheduling mammogram or refer to health plan for assistance with scheduling or other barrier resolution											
	Billi	ng Reference									
Description	C	PT	HCPCS	UB Revenue							
Breast Cancer Screening	77055-77057,	77061-77067	G0202, G0204, G0206	0401, 0403							
Measure Exclusion Criteria:											
mastectomy codes that 2018. Exclusion Description		tectomy on both the l	left and right side bef								
Bilateral Mastectomy			OHTV								
Hx. Bilateral Mastectomy	Z90).13									
· · ·		ctomy with Bilateral N	Modifier								
Exclusion Description		CP [.]									
Unilateral Mastectomy	1	.9180, 19200, 19220, 1	19240, 19303-19307								
·		ft) or RT (right) modifi									
Exclusion Description		ICD-10									
Listenal Maataatamay	Left	0HTU0ZZ	Right	OHTTOZZ							
Unilateral Mastectomy	Absence of Breast Left Z90.12 Right Z90.11										
Absence of Breast		Additional Exclusion Criteria									
Absence of Breast Additional Exclusion Criteria											
Absence of Breast Additional Exclusion Criteria Exclude from Medicare reporting	members age 6			-							
Absence of Breast Additional Exclusion Criteria Exclude from Medicare reporting who were enrolled in an Institutio	members age 6 onal SNP (I-SNP)) any time during the		-							
Absence of Breast Additional Exclusion Criteria Exclude from Medicare reporting who were enrolled in an Institution in an institution any time during t	members age 6 onal SNP (I-SNP) the measureme) any time during the nt year	measurement year o	r living long-tern							
Absence of Breast Additional Exclusion Criteria Exclude from Medicare reporting who were enrolled in an Institutio	members age 6 onal SNP (I-SNP) the measureme er as of 12/31 of) any time during the nt year f the measurement ye	measurement year o ear with Both advanc	r living long-term ed illness and							

CAP Children and Adolescents' Access to Primary Care Practitioners								
 Measure Definition: The percentage of members 12 months- 19 years of age who had a visit with a PCP. Four separate percentages are reported: Chidren 12-24 months and 25 months - 6 years who had a visit with a PCP during the measurement year Children 7-11 years and adolescents 12-19 years who had a visit with a PCP during the measurement year or the year prior to the measurement year 								
Common Chart Deficiencies and Tips: 1. Utilize your Gaps in Care report to outreach parents/guardians of children that have not had an appointment. 2. Stress importance of preventive visits during outreach								
	Billing Referen							
Description								
Description	C 99201-99205, 99211-99215, 99241-992	ce						
Description	C 99201-99205, 99211-99215, 99241-992	ce PT 245, 99341-99345, 99347-99350, 99381-						
Description Ambulatory Visits	C 99201-99205, 99211-99215, 99241-992 99387, 99391-99397, 99401	ce PT 245, 99341-99345, 99347-99350, 99381- -99404, 99411-99412, 99429						
Ambulatory	C 99201-99205, 99211-99215, 99241-992 99387, 99391-99397, 99401 HCPCS G0402, G0438, G0439, G0463, T1015	CCE PT 245, 99341-99345, 99347-99350, 99381- -99404, 99411-99412, 99429 UBREV						

CBP Controlling High Blood	BP Controlling High Blood Pressure						
	8–85 years of age who had a diagnosis of hypertension (HTN) controlled (<140/90) during the measurement year						
 Retake the blood pressure during a visit Ensure that the BP cuff is Check you BP cuffs to make 	 Ensure that the BP cuff is the correct size for patient's arm Check you BP cuffs to make sure they are providing accurate readings If using an automatic BP machine, record actual number Do Not Round 						
	Billing Reference						
Description	Description ICD-10 CM						
Essential Hypertension	sential Hypertension I10						
New for HEDIS 2019: Blood pressure CP	T II codes are acceptable to meet compliance!						
Systolic BP CPT II Codes	stolic BP CPT II Codes <130 3074F; 130-139 3075F; >/= 140 3077F						

< 80 9078F; 80-89 3079F; >/- 90 3080F

Diastolic BP CPT II Codes

CBP Controlling High Blood Pressure Exclusion Criteria								
Exclude from the eligible population all members with evidence of end-stage renal disease (ESRD) or kidney transplant on or prior to December 31 of the measurement year or a diagnosis of pregnancy during the measurement year.								
Exclusion Description	CPT ICD-10 PCS UB Revenue H				HCPCS			
Evidence of	36147, 36800 36815, 36818 36831-36833		36147, 36800, 36810, 36815, 36818-36821, 36831-36833, 90935, 90837, 90940, 90945,		3E1M39Z, 5A1D00Z, 5A1D60Z- 5A1D90Z	0800-0804, 0809, 0820-0825, 0829-0835, 0839-0845, 0849- 0855, 0859, 0880-0882, 0889		S9339, G0257
ESRD	90947, 90951		ICD-10 CM	UB Ty	ype of Bill	POS		
	-	90989, 90993, 90997, 90999, 99512		0720-0725, 727, 728, 072A-072K, 072M, 072O, 072X-072Z		65		
ESRD Obsolete	CPT G0308-G0319, G0921-G0323, G0325-G0327 36145, 90919-90925 G0392-G0393							
	СРТ	CPT ICD-1) PCS	UB Revenue	HCPCS		
Kidney Transplant	50300, 50320 50360, 50365 50380	5, 50370,	0TY00Z0 - 0TY10Z0 - ICD-1(294	0TY10Z2	367	S2065		
Descrip	tion		23-	ICD-10 CN	1			
Pregnancy			O00.	0-09A53, Z03.7				
Additional Exc	clusion Crite	ria						
	Exclude from Medicare reporting members age 66 and older as of 12/31 of the measurement year who were enrolled in an Institutional SNP or living long-term in an institution any time during the							
Exclude members age 66 to 80 as of 12/31 of the measurement year with BOTH advanced illness and frailty: a claim for an advanced illness condition from the measurement year or the year prior and a claim for frailty in the measurement year.								
Exclude member claim.	rs age 81 and c	older as o	f 12/31 of the m	-	ar who had at least of ional Committee for Quality As:	-		

Measure Definition	:			
	ntage of women 21–64 years of age who	were screene	ed for cervical cancer using	either of the
following	criteria:		_	
	Women age 21–64 who had cervical cyte	ology perform	ned within the last 3 years.	
	Women age 30–64 who had cervical cyte	ology with hu	man papillomavirus (HPV)	co-testing
	performed within the last 5 years.			
or 'radio 2. Docu not indi 3. Refle count	Common Chart Deficience imentation of hysterectomy must include cal' imentation of hysterectomy alone does in cate the cervix was removed x testing (performing HPV test <i>after</i> dete cal cytoloy and human papillomavirus te	e words such not meet guid ermining cytol	lelines because it does logy result) does NOT	
	Billing Refe	erence		
Description	СРТ	HCPCS		UB
Cervical Cancer Screening	88141-88143, 88147, 88148, 88150, 88152-88154, 88164-88167, 88174, 88175	G0123. G0124. G0141. G0143-G0145.		
IPV Tests	87620 - 87622, 87624-87625		G0476	
	on Criteria:			
Aeasure Exclusi			hoforo Docombor 21, 2019	•
	who had a hysterectomy with no residual	l cervix on or	belore December 51, 2016	
Measure Exclusion A female Exclusion Description	who had a hysterectomy with no residual CPT	l cervix on or	ICD-10 PCS	ICD-10 CM

CDC Comprehensive Diabetes Care - Blood Pressure Less Than 140/90

Measure Definition:

Members 18 to 75 years of age with diabetes (type 1 and type 2) whose last blood pressure in the measurement year was less than 140/90.

Tips:

1. CPT II codes for BP values are accepted for this measure

2. Retake blood pressure during the visit if it is initially elevated

- 3. Ensure that the BP cuff is the correct size for the patient's arm
- 4. If using an automated cuff, record actual numbers, don't round

up

Billing Reference					
Description		ICD-10 CM			
Diabetes		E10.10-E13.9, O24.011-O24.33, O24.811-O24.83			
CPT II	Codes to Identify	Systolic and Diastolic BP Levels <140/90			
Description		CPT II			
Systolic <130		3074F			
Systolic 130-139		3075F			
Systolic > or = 140		3077F			
Diastolic < 80		3078F			
Diastolic 80-89		3079F			
Diastolic > or = 90		3080F			
Measure Exclus	ion Criteria:				
Identify members w	ho do not have a dia	gnosis of diabetes, in any setting, during the measurement			
year or the year prio	r and who meet eith	er of the following criteria:			
•	•	etes or steroid-induced diabetes, in any setting, during the prior, with no encounters in any setting with a diagnosis of			
Exclusion [Description	ICD-10 CM			
Diabetes Exclusions		E08.00-E09.9, O24.410-O24.439, O24.911-O24.93			
Additional Exclusion	ion Criteria				
Exclude from Medica	re reporting members	s age 66 and older as of December 31st of the measurement			
year who were enroll	ed in an Institutional	SNP (I-SNP) any time during the measurement year or living			
long-term in an institution any time during the measurement year					
Exclude members age	e 66 and older as of 12	2/31 of the measurement year with BOTH advanced illness			
and frailty: a claim fo	and frailty: a claim for an advanced illness condition from the measurement year or the year prior and a				
claim for frailty durin HEDIS [®] stands for Healthcare Ef (NCQA).		ear required. on Set and is a registered trademark of the National Committee for Quality Assurance			

CDC Comprehensive Diabetes Care - Dilated Retinal Eye Exam

Measure Definition:

Members 18 to 75 years of age with diabetes (type 1 and type 2) who had a dilated retinal eye exam in the measurement year or a dilated retinal eye exam that was negative for retinopathy in the year prior to the measurement year.

Billing Reference						
Description		СРТ		CPT II	HCPCS	
	67028, 67030, 6703	1, 67036, 67039-67043, 67101,	67105,			
	67107, 67108, 6711	67145,	3072F,	60620		
Diabetic Retinal	67208, 67210, 6721	8, 67220, 67221, 67227, 67228,	92002,	2022F,	S0620, S0621,	
Screening	92004, 92012, 9201	4, 92018, 92019, 92134, 92225-	92228,	2024F,	S30021,	
	92230, 92235, 9224	0, 92250, 92260, 99203-99205,	99213-	2026F	33000	
		9215, 99242-99245				
	-	s - ICD10CM - billed with a		ICD10CM		
	eening code during th	e year prior to the	F'	10.9, E11.9, E	13.9	
measurement year	meets compliance			th dates of sei		
Unilateral Eye	65001 65003 65101	, 65103, 65105, 65110, 65112,		lays apart or set		
Enucleation	65114	., 05103, 05105, 05110, 05112,		bilateral mod	-	
Lindcleation	05114		with a	50, 9950		
Description		ICD-10 PCS		30, 3330		
Unilateral Eye						
Enucleation, Left	08B10ZX, 08B10ZZ, 08B13ZX, 08B13ZZ, 08B1XZX, 08B1XZZ					
Unilateral Eye Enucleation, Rt	08B00ZX, 08B00ZZ, 08B03ZX, 08B03ZZ, 08B0XZX, 08B0XZZ					
Measure Exclusi	on Criteria:					
Identify members w	vho do not have a dia	agnosis of diabetes, in any setti	ng, durin	g the measur	ement	
year or the year pri	or and who meet eith	ner of the following criteria:				
A diagnos	sis of gestational diab	petes or steroid-induced diabet	es, in any	y setting, in th	e	
measurei	ment year or the year	[,] prior				
Exclusion	Description	ICD-	10 CM			
Diabetes Exclusions	5	E08.00-E09.9, O24.410-	024.439	, 024.911-024	1.93	
Additional Exclu	sion Criteria					
Exclude from Medic	are reporting member	s age 66 and older as of Decemb	er 31st o	f the measure	ment year	
who were enrolled in an Institutional SNP (I-SNP) any time during the measurement year or living long-term						
in an institution any	in an institution any time during the measurement year					
		2/31 of the measurement year v				
-		ndition from the measurement y	ear or the	e year prior an	d a claim	
	e measurement year re	equired. ion Set and is a registered trademark of the Nat	ional Commit	too for Quality Accur		
TEDIS" STATUS FOR HEALTICARE	Enectiveness Data and informat	ion Set and is a registered trademark of the Nat	ional Commit	tee for quality Assur	ance (INCQA).	

CDC Comprehensive Diabetes Care - HbA1c Testing

Measure Definition:

Members 18 to 75 years of age with diabetes (type 1 and type 2) who had an HbA1c test during the measurement year.

Common Chart Deficiencies and Tips:

- **1.** Educate member on importance of completing A1C test.
- 2. Lab results not documented in chart
- 3. Lab values show poor control (>9).


Billing Reference					
Description	ICD-10 CM				
Diabetes	E10.10-E13.9, O24.011-O24.13, O24O311-24.33, O24.811-O24.8				
Description			СРТ		
HbA1c Screening		83	3036, 83037		
Description		Lab Result	CPT II		
		<7%	3044F		
HbA1c Result		7.0% - 9.0%	3045F		
		>9.0%	3046F		
Measure Exclusion Crite	eria:				
Identify members who do not have a diagnosis of diabetes, in any setting, during the measurement year or the year prior <u>and</u> who meet either of the following criteria: A diagnosis of gestational diabetes or steroid-induced diabetes, in any setting, during the measurement year or the year prior, with no encounters in any setting with a diagnosis of diabetes.					
Exclusion Description	n		ICD-10 CM		
Diabetes Exclusions		E08.00-E09.9, O24.410-O24.439, O24.911-O24.93			
Additional Exclusion Criter	ia				
Exclude from Medicare reporting members age 66 and older as of December 31st of the measurement year who were enrolled in an Institutional SNP (I-SNP) any time during the measurement year or living long-term in an institution any time during the measurement year Exclude members age 66 and older as of 12/31 of the measurement year with BOTH advanced illness and					
			urement year or the year prior and a		
claim for frailty during the measu		•			
HEDIS [®] stands for Healthcare Effectiveness Data (NCQA).	and Informatio	n Set and is a registered traden	nark of the National Committee for Quality Assurance		

CDC Comprehensive Diabetes Care -
Medical Attention for Nephropathy

Measure Definition:

Members 18 to 75 years of age with diabetes (type 1 and type 2) who received medical attention for nephropathy in during the measuremnet year through one of the following:

- A urine test for protein with minimum documentation of date and result
- Documentation of a visit to a nephrologist
- Documentation of a renal transplant
- Documentation of medical attention for any of the following: diabetic nephropathy, ESRD, CRF, CKD, renal insufficiency, proteinuria, albuminuria, renal dysfunction, ARF, dialysis, hemodialysis or peritoneal dialysis
- Evidence of ACE inhibitor/ARB therapy



Medical Attention for Nephropathy									
Descript	ion	СРТ	CPT II						
Urine Protein Tests 81000-8		81000-82	1003, 81005	003, 81005, 82042-82044, 84156 3060F, 3061F, 3062F					
Descript	ion	CPT II			ICD-10 (CM			
Treatment for Nephropathy 3066F, 4010-F		4010-F	F13.21-F13.29, 112.0-113.2, 115.0-115.1, N00.0-N08, N14.0-						
CDC Medical A	ttention f	-							
		Medica	I Attentio	n for Nep	hropathy				
Exclusion Description	СР	т	ICD-10 PCS		UB Reve	enue		HCPCS	
36147, 3 36810, 3 36818-3	36815, 36821,	3E1M39Z, 5A1D00Z, 5A1D60Z- 5A1D90Z	0839-0845.0849-0855.0859.0880-0882.1			S9339, G0257			
Evidence of ESRD	90935, 9 90940, 9	36831-36833 90935, 90837 90940, 90945	90837, 90945,	ICD-10 CM		UB Туре	of Bill		POS
	90947, 90951- 90970, 90989, 90993, 90997, 90999, 99512		N18.5, N18.6, Z91.15, Z99.2	0720-0725, 727, 728, 072A-072K, 072M, 072O, 072X-072Z			65		
Kidney		СРТ		ICD-10 CM	ICD-1	0 PCS	UB Rev	HCPCS	
Transplant	-)320, 5034 5, 50370, 1	40, 50360, 50380	Z94.0		- 0TY00Z2 <i>,</i> - 0TY10Z2	367	S2065	
Descript				IC	D-10 CM				
Stage 4 Chronic K Disease	idney				N18.4				

CDC Medical Attention for Nephropathy continued					
Medical Attention for Nephropathy					
Description	ACE Inhibitors/ARBs				
Angiotensin	Benazepril		Moexipril		
converting	Captopril		Perindopril		
•	Enalapril		Quinapril		
enzyme	Fosinopril		Ramipril		
inhibitors	Lisinopril		Trandolapril		
	Azilsartan		Losartan		
Angiotensin II	Candesartan		Olmesartan		
inhibitors	Eprosartan		Telmisartan		
	Irbesartan		Valsartan		
	Amlodipine-benazep	ril	Fosinopril-hydrochlorothiazide		
	Amlodipine-hydroch	lorothiazide-valsartan	Hydrochlorothiazide-irbesartan		
	Amlodipine-hydroch olmesartan	lorothiazide-	Hydrochlorothiazide-lisinopril		
			Hydrochlorothiazide-losartan		
Anti-	Amlodipine-perindo		Hydrochlorothiazide-moexipril		
Hypertensive	Amlodipine-telmisartan		Hydrochlorothiazide-olmesartan		
Combinations	Amlodipine-valsartan		Hydrochlorothiazide-quinapril		
	Azilsartan-chlorthalidone		Hydrochlorothiazide-telmisartan		
	Benazepril-hydrochlo	orothiazide	Hydrochlorothiazide-valsartan		
	Candesartan-hydrocl		Sacubitril-valsartan		
	Captopril-hydrochlor		Trandolapril-verapamil		
	Enalapril-hydrochlor	othiazide			
Measure Exc	lusion Criteria:				
Identify member	s who do not have a d	liagnosis of diabetes, i	n any setting, during the measurement		
		ither of the following o			
A diagn	osis of gestational dia	betes or steroid-induc	ed diabetes, in any setting, during the		
•	•		nters in any setting with a diagnosis of		
diabete	-	··· P·····) ······ ··· ··· ···			
	Description		ICD-10 CM		
Diabetes Exclusio		E08.00-E09.9, O	24.410-024.439, 024.911-024.93		
Additional Exc	lusion Criteria				
		ers age 66 and older as	of December 31st of the measurement		
		-	during the measurement year or living		
-		ing the measurement y			
	-	• •	nent year with BOTH advanced illness		
	-		neasurement year or the year prior and a		
-	uring the measuremen		. , .		
			mark of the National Committee for Quality Assurance		

CHL Chlamydia Screening in Women							
Measure Definitio	on:						
The percentage of women 16–24 years of age who were identified as sexually active and who had at least one test for chlamydia dueing the measurement year.							
Billing Reference							
Description	СРТ						
Chlamydia Test	87110, 87270, 87320, 87490-87492, 878	310					
Measure Exclus	sion Criteria:						
	n: Exclude female members who qualified for the denomin by test alone and who meet either of the following:	nator based on a					
A pregnancy test in the measurement followed within seven days (inclusi by a prescription for isotretinoin.							
A pregnancy test in the measurement year followed within seven days (inclusive) by an x-ray.							
Exclusion Description	СРТ	UB Revenue					
Pregnancy Test Exclusion	81025, 84702, 84703	925					
	WITH						
Exclusion Description	СРТ	UB Revenue					
Diagnostic Radiology	70010-76499	0320-0324, 329					
OR							
Retinoid	Isotretinoin Prescription						
HEDIS [®] stands for Healthca (NCQA).	re Effectiveness Data and Information Set and is a registered trademark of the National C	Committee for Quality Assuranc					

CIS Childhood Immunization Status

Measure Definition:

The percentage of children turning 2 years of age during the measurement year who received recommended vaccinations prior to their second birthday. Recommended vaccinations and # in series to meet compliance listed below.

The measure calculates a rate for each vaccine and nine separate combination rates.

Common Chart Deficiencies and Tips:

1. Vaccinations for DTaP, IPV, HiB, or PCV given before 42 days after birth date do not count towards vaccine compliance

- 2. Participate in State Immunization registries, where available
- **3.** Devote time during each visit to review immunization record and look for opportunities to catch-up on missing immunizations
- 4. Document date of first hepatitis B vaccination if given at hospital and note the hospital
- 5. Document history of illness in chart if child has had Varicella Zoster, measles,

Billing Reference							
Immunization Description	# in Series	СРТ	СVХ				
DTaP	4	90698, 90700, 90721, 90723	20, 50, 106, 107, 110, 120				
IPV	3	90698, 90713, 90723	10, 89, 110, 120				
MMR	1	90707, 90710	03, 94				
Any Combination of	the follow	ving to satisfy recommendation of	1 MMR				
Measles Only	1	90705	05				
Mumps Only	1	90704	07				
Rubella Only	1	90706	06				
Measles and Rubella	1	90708	04				

CIS Billing Reference continued									
Description	# in Series	СРТ	CVX						
Hib	3	3 90644-90648, 90698, 90721, 90748 17, 46-51, 120, 148							
Hepatitis B	3	3 90723, 90740, 90744, 90747, 90748 G0010 08, 44, 45, 51, 110							
vzv	1	90710, 90716		21, 94					
Pneumococcal Conjugate	4	90669, 90670	G0009	100, 133, 152					
Hepatitis A	1	1 90633 31, 83, 85							
Rotavirus 2-dose or 3-dose vaccinations satisfy Rotavirus recommendations.									
Rotavirus 2-dose	2	2 90681 119							
Rotavirus 3-dose	3	3 90680 116, 122							
Influenza	2	90655, 90657, 90661, 88, 135, 140, 141, 150, 90662, 90673, 90685- 90688							
ICD-10 CM Codes for Illnesses									
Hepatitis A B15.0, B15.9									
lepatitis B B16.0-B16.2, B16.9, B17.0, B18.0, B18.1, B19.10, B19.11, Z22.51									
Measles	B05.0-B05.4, B05.81, B05.89, B05.9								
Mumps	B26.0-B26.3, B26.81-B26.85, B26.89-B26.9								
Rubella	В06.00-В	B06.00-B06.02, B06.09, B06.81-B06.82, B06.89, B06.9							
Varicella Zoster	-	1.11-B01.2, B01.81-B01.9, B0 02.7-B02.9	02.0, B02.1, I	302.21-B02.29, B02.30-					

CIS Measure Exclusion Criteria:	010 0 0		_	•	~ •• •
CIS MEASURE EXClusion Cincenta.		ABCILLA	LVC	lucion	Critoria
		icasui c	LAU	lusion	CITCHA.

Exclusion: Exclude children who had a contraindication for a specific vaccine.

	· · · · · · · · · · · · · · · · · · ·			
Exclusion Description	ICD-10 CM			
Any particular vaccine - Anaphylactic Reaction	T80.52XA, T80.52XD, T80.52XS			
DTaP - Encephalopathy with	G04.32			
	WITH			
Adverse-Effect	T50.A15A, T50.A15D, T50.A15S			
For MRR, VZV and Influenza vaccines: Immunodeficiency, Lymphoreticular cancer, multiple myeloma or leukemia, or HIV	D80.0-D81.2, D81.4, D81.6-D82.4, D82.8- D83.2, D83.8- D84.1, D84.8-D84.9, D89.3, D89.810-D89.13, D89.82, D89.89, D89.9, B20, Z21, B97.35, C81.00-C86.6, C88.2- C88.9, C90 - C96.Z			
Rotavirus - Severe combined immunodeficiency or a history of intussusception	D81.0-D81.2, D81.9, K56.1			
Exclusion Description	General Exclusion Criteria			
MRR, VZV and Influenza	Anaphylactic reaction to neomycin			
	Anaphylactic reaction to streptomycin, polymyxin B, or			
IPV	neomycin			
Hepatitis B	Anaphylactic reaction to common baker's yeast			
IEDIS® stands for Healthcare Effectiveness Data and Information Set and is a registered trademark of the National Committee for Quality Assurance (NCQA).				

COA Care for Older Adults							
Measure Definition: The percentage of adults 66 years and older who had each of the following during the measurement year: Advance care planning. Medication review. Functional status assessment. Pain assessment. Pain assessment. Common Chart Deficiencies and Tips Advance Care Planning - document discussion and/or presence of advance directive or living will in chart Medication Review - Medication list in chart and medication review by prescribing provider annually - signed and dated							
 prescribing provider annually - signed and dated 3. Functional Status Assessment - address cognitive and ambulation status, sensory ability, and functional independence. 4. Pain Assessment - documentation of pain screening result (postiive or negative) 							
	Billing R	eferer	nce				
Description	СРТ	ICD1	0 CM	HCPCS	CPT Category II		
Advance Care Planning	99497	Z66		S0257	1123F, 1124F, 1157F, 1158F		
Medication List				G8427	1159F		
With one of the following Medication Review codes on the same claim:							
Medication Review	90863, 99605, 99606,				1160F		
Transitional Care Management Codes alone meet Medication Review compliance							
TCM codes:	99495, 99496						
Functional Status Assessment		G04		3, G0439	1170F		
Pain Assessment					1125F, 1126F		
HEDIS [®] stands for Healthcare Effectiveness Data and Information Set and is a registered trademark of the National Committee for Quality Assurance (NCQA).							

COL Colorectal Cancer Screening								
Measure Definition:								
	e of membe	ers 50–75 vears of ag	e who had appropriate s	creening for				
	The percentage of members 50–75 years of age who had appropriate screening for colorectal cancer.							
		Tince						
Tips: 1. A fecal occult test done in the office via a digital rectal exam does not count								
		Billing Referen	ce					
Description	1		СРТ	HCPCS				
Fecal occult blood test (0000	0 00074	G0328				
samples- or iFOBT in 201	L8)	8227	70, 82274	G0328				
FIT-DNA test (between 2 2018)	2016 and	8	31528	G0464				
Flexible Sigmoidoscopy	(between	45330-45335, 4533	37-45342, 45345-45347,	60104				
2014 and 2018)	G0104							
Colonoscopy (between 2009 and 44388-44394, 44397,44401-44408, 45355, 45318) 45378-45393, 45398 G0105, G0121								
CT Colonography (between 2014 and 2018) 74261-74263								
Measure Exclusion Criteria:								
Evidence of Colorectal C	ancer or Tot	tal Colectomy throug	h December 31, 2018.					
Exclusion ICD-10 CM								
Colorectal Cancer	C18.0-C18.9, C19, C20, C21.2, C21.8, C78.5, Z85.038, Z85.048							
		СРТ	ICD-10 PC	CS				
Total Colectomy	44150-44153, 44155-44158, 44210-44212 ODTE0ZZ, 0DTE4ZZ, 0DTE7ZZ, 0DTE8ZZ							
Additional Exclusion Criteria								
Exclude from Medicare reporting members age 66 and older as of December 31st of the measurement year who were enrolled in an Institutional SNP (I-SNP) any time during the								
measurement year or living long-term in an institution any time during the measurement year								
Exclude members age 66 and older as of 12/31 of the measurement year with BOTH advanced								
illness and frailty: a claim for an advanced illness condition from the measurement year or the year								
prior and a claim for frailty during the measurement year required.								
HEDIS [®] stands for Healthcare Effectiveness Data and Information Set and is a registered trademark of the National Committee for Quality Assurance (NCQA).								

Measure Definition:	Testing for Childre					
	f members 2–18 years of ag	e diagnosed with pharyngitis, dispensed an				
The percentage of members 2–18 years of age diagnosed with pharyngitis, dispensed an antibiotic and received a group A streptococcus (strep) test.						
	Common Chart Deficio	encies and Tips				
1. Perform a group A Strep Test on all children before treating with						
an antibio	otic for pharyngitis					
2. Submit	t the claim for the group A St	trep Test				
	Billing Refe	rence				
Description		ICD-10 CM				
Pharyngitis		03.01, J03.80-J03.81, J03.90-J03.91				
, .	JUZ.U, JUZ.0-J					
Description		СРТ				
Group A Strep Tests	87070, 87071,	87081, 87430, 87650-87652, 87880				
· ·						
Antibiotic Medications						
Description	Prescriptions					
Aminopenicillins	Amoxicillin	Amoxicillin Ampicillin				
Beta-lactamase inhibitors	Amoxicillin-clavulanate	Amoxicillin-clavulanate				
First generation	Cefadroxil	Cephalexin				
cephalosporins	Cefazolin					
Folate antagonist	Trimethoprim					
Lincomycin derivatives	Clindamycin					
Maavalidaa	Azithromycin	Erythromycin ethylsuccinate				
Macrolides	Clarithromycin Erythromycin	Erythromycin lactobionate Erythromycin stearate				
	Penicillin G potassium	Penicillin V potassium				
Natural penicillins	Penicillin G sodium					
Penicillinase-resistant	Dicloxacillin					
	Ciprofloxacin	Moxifloxacin				
Quinolones	Levofloxacin	Ofloxacin				
Second generation	Cefaclor Cefuroxime					
cephalosporins	Cefprozil					
Sulfonamides	Sulfamethoxazole-trimethoprim					
Tetracyclines	Doxycycline	Tetracycline				
. ett augunnes	-	Minocycline				
Third generation	Cefdinir	Ceftibuten				
cephalosporins	Cefixime	Cefditoren				
• • • •	Cefpodoxime	Ceftriaxone				

DAE Use of High-Risk M	edications in the Elde	rly				
Measure Definition:						
1. The percentage of Medi	care members 66 years of age an	d older who received at least one				
high-risk medication dispensing event in the measurement year.						
2. The percentage of Medi	care members 66 years of age an	d older who received at least two				
	ions dispensing events in the me					
For both rates, a lower rat	e represents better performance.					
	igh-risk medication is define					
A dispensed prescriptio	n from High-Risk Medications tak	ole.				
Dispensed prescriptions	s that meet days supply criteria fr	om High-Risk Medications With Days				
Supply Criteria table.						
A dispensed prescriptio	n that meets average daily dose o	criteria from High-Risk Medications				
With Average Daily Dos	e Criteria table.					
	Billing Reference					
	High-Risk Medications					
Description	Pre	scription				
	Brompheniramine	Diphenhydramine (oral)				
	Carbinoxamine	Dimenhydrinate				
Anticholinergics, first-generation	Chlorpheniramine	Doxylamine				
antihistamines	Clemastine	Hydroxyzine				
antinistanines	Cyproheptadine	Meclizine				
	Dexbrompheniramine	Promethazine				
	Dexchlorpheniramine	Triprolidine				
Anticholinergics, anti-Parkinson agents	Benztropine (oral)	Trihexyphenidyl				
	Dicyclomine	Hyoscyamine				
Anticnocmodice	Belladonna alkaloids	Propantheline				
Antispasmodics	Clidinium-chlordiazepoxide	Scopolamine				
	Atropine (exclude ophthalmic)					
Antithrombotics	Dipyridamole, oral short-acting (does not apply to the extended-release combination with aspirin)					
	Ticlopidine					
Cardiovascular, alpha agonists, central	Guanfacine	Methyldopa				
Cardiovascular, other	Disopyramide	Nifedipine, immediate release				
	Amitriptyline	Trimipramine				
	Clomipramine	Nortriptyline				
Central nervous system,	Amoxapine	Paroxetine				
antidepressants	Desipramine	Protriptyline				
	Imipramine					

High-Risk Medications continued							
Description		Prescription					
Central nervous system				Pentobar Phenoba			
Darbiturates	Butalbita	Butalbital Secobarbit		ital			
Central nervous system, vasodilators	Ergot me	rgot mesylates Isoxsuprine					
Central nervous system, o	ther	Meproba	/leprobamate				
Endocrine system, estroge or without progestins; inclu		Conjugat	ed estrogen	Estradiol			
oral and topical patch products		Esterifie	d estrogen	Estropipa	te		
Endocrine system, sulfony long-duration	lureas,	Chlorpro	pamide	Glyburide	9		
Endocrine system, other		Desiccat	ed thyroid	Megestro)I		
Pain medications, skeletal	mussla	Carisopro	odol	Metaxalo	Metaxalone		
relaxants	muscie	Chlorzox	azone	Methocarbamol			
relaxants		Cyclobenzaprine		Orphenadrine			
		Indomethacin		Meperidine			
Pain medications, other	Ketorolac, includes parenteral		Pentazocine				
H	Medicat	tions With Days Supp	oly Criter	ia			
Description		Prescription				Days Supply Criteria	
Anti-Infectives, other	Nitrofura	ntoin Nitrofurantoin macrocrystals- monohydrate			>90 days		
	Nitrofura	ntoin macrocrystals					
Nonbenzodiazepine	Eszopiclo	ne	Zolpidem			->90 days	
hypnotics	•	Zaleplon			t e ut e		
Description		dications With Average Daily Dose Control Prescription		Average Daily Dose Criteria			
Alpha agonists, central		Reserpine			>0.1 mg/day		
Cardiovascular, other	Digoxin			>0.125 mg/day			
Tertiary TCAs (as single ag part of combination produ	Doxepin			>6 mg/da	ау		
HEDIS [®] stands for Healthcare Effectiven	ess Data and In	formation Set	and is a registered trademark of the	National Comm	ittee for Quali	ty Assurance (NCQA).	

DDE Potentially Harmful Drug-Disease Interactions in the Elderly

Measure Definition:

The percentage of Medicare members 65 years of age and older who have evidence of an underlying disease, condition or health concern and who were dispensed an ambulatory prescription for a potentially harmful medication, concurrent with or after the diagnosis.

Three individual rates and a total rate reported:

1. A history of falls and a prescription for anticonvulsants, SSRIs, antipsychotics, benzodiazepines, non-benzodiazepine hypnotics or tricyclic antidepressants.

2. Dementia and a prescription for antipsychotics, benzodiazepines, non-benzodiazepine hypnotics, tricyclic antidepressants, H2 receptor antagonists or anticholinergic agents.

3. Chronic kidney disease and a prescription for Cox-2 selective NSAIDs or nonaspirin NSAIDs

Billing Reference								
Description	ICD-10 CM							
Falls	Any fall or measure	Any fall or hip fracture ICD10 or CPT code pulls the member into this measure						
Dementia	F01.5, F01.51, F02.80, F02.81,F03.90, F03.91, F04, F10.27, F10.97, F13.27, F13.97, F18.17, F18.27, F18.97, F19.17, F19.27, F19.97, G30.0, G30.1, G30.8, G30.9, G31.83							
Chronic Kidney Disease Stage 4	N18.4							
Description	ICD-10 CM	ICD-10 PCS	HCPCS	СРТ				
ESRD	N18.5, N18.6, Z91.15, Z99.2	3E1M39Z, 5A1D00Z, 5A1D60Z- 5A1D90Z	G0257, S9339	36147, 36800, 36810, 36815, 36818- 36821, 36831-36833, 90935, 90937, 90940, 90945, 90947, 90951-90970, 90989, 90993, 90997, 90999, 99512				
Kidney Transplant	Z94.0	OTY00Z0 - 0TY00Z2. 50300. 50320. 50340. 50360. 5036						

Potentially Harmful Medications							
Potentially Harmful Drugs - Rate 1							
Description	Prescription						
	Carbamazepine	Felbamate	ide	Tiagabine HCL			
	Clobazam	Fosphenyto	in	Oxcarbazep	oine	Topiramate	
Anticonvulsants	Divalproex sodium	Gabapentin		Phenytoin		Valproate sodium	
Anticonvuisants	Ethosuximide	Lacosamide	1	Pregabalin		Valproic acid	
	Ethotoin	Lamotrigine	9	Primidone		Vigabatrin	
	Ezogabine	Levetiraceta	am	Rufinamide		Zonisamide	
SSRIs	Citalopram	Fluoxetine		Paroxetine			
	Escitalopram	Fluvoxamin	e	Sertraline			
Potentially Harmful I	Drugs - Rate 1 and Ra	ite 2					
Description	Prescription						
	Aripiprazole	Fluphenazine		Olanzapine		Thioridazine	
	Asenapine	Haloperidol		Paliperidone		Thiothixene	
Antipsychotics	Brexpiprazole	lloperidone		Perphenazine		Trifluoperazine	
Antipsychotics	Cariprazine	Loxapine		Pimozide		Ziprasidone	
	Chlorpromazine	Lurasidone		Quetiapine			
	Clozapine	Molindone		Risperidone			
	Alprazolam		Estazolam	Estazolam		n	
	Chlordiazepoxide pro	oducts	Flurazepam I	HCL	Temazepa	am	
Benzodiazepines	Clonazepam		Lorazepam		Triazolam		
	Clorazepate-dipotas	sium	Midazolam HCL				
	Diazepam		Oxazepam				
Nonbenzodiazepine	Eszopiclone		Zaleplon		Zolpidom		
hypnotics					Zolpidem		
Tricyclic	Amitriptyline		Desipramine		Nortripty	ine	
antidepressants	Amoxapine		Doxepin (>6	mg)	Protriptyl	ine	
antiucpressants	Clomipramine		Imipramine		Trimipran	nine	

Potentially Harmful Medications continued							
Potentially Harmful I	Drugs - Rate 2						
Description			Prescrip	otion			
H2 receptor	Cimetidine	Famotidine		Nizatidina		Ranitidine	
antagonists	Cimetiume	Famotiume		Nizatidine		Kanitiume	
Anticholinergic							
agents,	Prochlorperazine	Promethazine	9				
antihistamines							
	Carbinoxamine	Triprolidine		Dexbromp	neniramine	2	
Anticholinergic	Chlorpheniramine	Cyprohepta	dine	Dexchlorph	ieniramine		
agents,	Hydroxyzine	Dimenhydri	nate	Doxylamine	2		
antihistamines	Brompheniramine	Diphenhydr	amine				
	Clemastine	Meclizine					
Anticholinergic	Atropine		Dicyclomine		Scopolam	ine	
agents,	Homatropine		Hyoscyamine	<u>j</u>	Clidinium-	-chlordiazepoxide	
antispasmodics	Belladonna alkaloids		Propanthelin	е			
Anticholinergic	Darifenacin	Flavoxate		Solifenacin		Trospium	
agents,	Darmenacin	FlavOxate		Somenacii		rrospium	
antimuscarinics	Fesoterodine	Overhutzmin		Tolterodine			
(oral)	resoleroume	Oxybutynin		Tonerounie			
Anticholinergic							
agents, anti-	Benztropine	Trihexypher	nidyl				
Parkinson agents							
Anticholinergic							
agents, skeletal	Cyclobenzaprine	Orphenadri	ne				
muscle relaxants							
Anticholinergic	Paroxetine						
agents, SSRIs	raiozetine						
Anticholinergic							
agents,	Disopyramide						
antiarrthymics	.,						
· · · · · · · · · · · · · · · · · · ·	Drugs - Selective NSA	IDs and Non	aspirin NSALD	s Rate 3			
Description			Prescrip				
Cox-2 Selective			reserr				
NSAIDs	Celecoxib						
	Diclofenac potassiun	1	Ketoprofen		Naproxen	sodium	
	Diclofenac sodium		Ketorolac		Oxaprozin		
	Etodolac		Meclofenam	ate	Piroxicam		
Nonaspirin NSAIDs	Fenoprofen		Mefenamic a		Sulindac		
	Flurbiprofen		Meloxicam		Tolmetin		
	Ibuprofen		Nabumetone		lonneum		
	· · ·				-		
	Indomethacin Naproxen						

Measure Definition:						
The percentage of discharges for members 6 years of age and older who were hospitalized						
for treatment of selected mental illness diagnoses who had an outpatient visit, an						
intensive outpatient encounter or partial hospitalization with a mental health						
practitioner. Two rates are reported:						
The percentage of discharges for which the member received follow-up within						
30 days of discharge.						
-	-	for whic	ch the	member received follow-up within 7		
days of dis				······································		
**Visits on the same day a	-	ot mee	et crit	eria		
	Billing R					
Codes to Identify				ntal Health Practitioner		
CPT				HCPCS		
98960-98962, 99078, 99201-99	205, 99211-99215,	G01	55, G0	176, G0177, G0409, G0463, H0002,		
99241-99245, 99341-99345, 99347-99350, 99381- H0004, H0031, H0034, H0036-H0037, H003				0031, H0034, H0036-H0037, H0039,		
99387, 99391-99397, 9940	L-99404, 99411,	Н00	40 <i>,</i> H2	2000, H2010, H2011, H2013-H2020,		
99412, 99510			M0064, T1015			
UBREV				ТСМ СРТ		
510, 513, 515-517, 519-523, 5	26-529, 900, 902-			99495, 99496		
904, 911, 914-917, 91	9, 982, 983					
	(DR		200		
CPT			Г	POS		
90791, 90792, 90832-9083						
90845, 90847, 90849, 9085		WITH	2, 3, 5	5 7, 9, 11-20, 22, 33, 49, 50, 52, 53, 7		
99221-99223, 99231-99233, 99	238, 99239, 99251-			72		
99255						
All of the Ab				nodifier CPT: 95, GT		
	Obsei	vation	1			
СРТ			1.00	99217-99220		
	Partial Ho	ospital	/10P			
HCPCS				UBREV		
G410, G411, H0035, H2001, H2				905, 907, 912, 913		
\$9484, \$948		ulcivo T	- hora	~ V		
СРТ	Electroconvu ICD10P		nera	UBREV		
90870 GZB0ZZZ-GZB4ZZZ 901 Any ECT code with POS code: 3, 5 ,7 ,9 , 11-20, 22, 23, 33, 49, 50, 52, 53, 71, 72						

IMA Immunizations for Adolescents

Measure Definition:

The percentage of adolescents turning 13 years of age in the measurement year who received one dose of meningococcal conjugate vaccine, one tetanus, diphtheria toxoids and acellular pertussis vaccine (Tdap) and completed the human papillomavirus (HPV) vaccine series by their 13th birthday. The

measure calculates a rate for each vaccine and two combination rates:

•Tdap and Meningococcal conjugate

•Tdap, Meningococcal conjugate and HPV

Common Chart Deficiencies and Tips:

1. Participate in State Immunization registries, where available

2. Devote time during each visit to review immunization record and look

for opportunities to catch-up on missing immunizations

3. Meningococcal recombinant serogroup B does NOT count

4. Educate teens and parents/guardians about the importance of these immunizations.

Meningococcal Vaccine - At least one meningococcal serogroups A, C, W, Y vaccine administered between the 11th and 13th birthday

Tdap Vaccine - administered between the 10th and 13th birthday

HPV - two HPV vaccines between the 9th and 13th birthday with at least 146 days between the doses OR three doses with different dates of service between the 9th and 13th birthday.

Billing Reference						
Description	СРТ	CVX				
Tdap	90715	115				
Meningococcal	90734	108, 114, 136, 147, 167				
Human Papillomavirus	90649, 90650, 90651	62, 118, 137, 165				
Measure Exclusion Criteria:	·					
Exclusion: Exclude children who had a contraindication for a specific vaccine.						
Exclusion Description	Exclusion Description ICD-10 CM					
Anaphylactic Reaction	T80.52XA, T80.52)	(D, T80.52XS				
	G04.32					
DTaP - Encephalopathy with Adverse-Effect	WITH					
	T50.A15A, T50.A15D, T50.A15S					
HEDIS [®] stands for Healthcare Effectiveness Data and Information Set and is a registered trademark of the National Committee for Quality Assurance (NCQA).						

LBP Use of	BP Use of Imaging Studies for Low Back Pain					
Measure Definiti	on:					
The perc	entage of members with a primary diagnosis o	of low back pain who did <u>not</u> have an imaging				
study (p	lain X-ray, MRI, CT scan) within 28 days of the	diagnosis. This measure is for members aged				
18-50 ye	ars old.					
	*Inverted Measure: Numerator identifies app	ropriate treatment of low back pain (i.e., the				
	proportion for whom imaging studies did not					
	Billing Referen	ce				
	ICD-10 CM Diagnosis Uncomplic	ated Low Back Pain				
 M47.26-M47.28, M47.816-M47.818, M47.896-M47.898, M48.06-M48.08, M51.16, M51.17, M51.26, M51.27, M51.36, M51.37, M51.86, M51.87, M53.2X6-M53.2X8, M53.3, M53.86-M53.88, M54.16-M54.18, M54.30-M54.32, M54340-M54.42, M54.5, M54.89, M54.9, M99.03-M99.04, M99.23 -M99.84, S33.100A, S33.100D, S33.100D, S33.110A, S33.110D, S33.110S, S33.120D, S33.120D, S33.120S, S33.130A, S33.130D, S33.130S, S33.140A, S33.140D, S33.140D, S33.140D, S33.5XXA, S33.6XXA, S33.9XXA, S39.002A, S39.002D, S39.002S, S39.012A, S39.012D, S39.012S, S39.092A, S39.092D, S39.092S, S39.82XA, S39.82XD, S39.82XS, S39.92XA, S39.92XD, S39.92XD 						
Description	Description CPT UB Revenue					
72010, 72020, 72052, 72100, 72110, 72114, 0320, 0329, 0350, 0352, 0359, 0610, 0612						
	72120, 72131-72133, 72141, 72142, 72146-	0320, 0329, 0350, 0352, 0359, 0610, 0612, 0614, 0619, 0972				
	72120, 72131-72133, 72141, 72142, 72146- 72149, 72156, 72158, 72200, 72202, 72220					
Imaging Studies	72120, 72131-72133, 72141, 72142, 72146- 72149, 72156, 72158, 72200, 72202, 72220	0614, 0619, 0972				
Imaging Studies	72120, 72131-72133, 72141, 72142, 72146- 72149, 72156, 72158, 72200, 72202, 72220 sion Criteria:	0614, 0619, 0972 istory:				
Imaging Studies	72120, 72131-72133, 72141, 72142, 72146- 72149, 72156, 72158, 72200, 72202, 72220 sion Criteria: Anytime in member's h	0614, 0619, 0972 istory: plant, HIV				
Imaging Studies	72120, 72131-72133, 72141, 72142, 72146- 72149, 72156, 72158, 72200, 72202, 72220 sion Criteria: Anytime in member's h Cancer, Major Organ Trans	0614, 0619, 0972 istory: plant, HIV				
Imaging Studies	72120, 72131-72133, 72141, 72142, 72146- 72149, 72156, 72158, 72200, 72202, 72220 sion Criteria: Anytime in member's h Cancer, Major Organ Trans Any time during the 3 months prior to the c	0614, 0619, 0972 istory: plant, HIV liagnosis of low back pain:				
Imaging Studies	72120, 72131-72133, 72141, 72142, 72146- 72149, 72156, 72158, 72200, 72202, 72220 sion Criteria: Anytime in member's h Cancer, Major Organ Trans Any time during the 3 months prior to the o Recent Trauma	0614, 0619, 0972 istory: plant, HIV liagnosis of low back pain:				
Imaging Studies Measure Exclu	72120, 72131-72133, 72141, 72142, 72146- 72149, 72156, 72158, 72200, 72202, 72220 sion Criteria: Anytime in member's h Cancer, Major Organ Trans Any time during the 3 months prior to the o Recent Trauma Any time during the 12 months prior to lo	0614, 0619, 0972 istory: plant, HIV liagnosis of low back pain: ow back pain diagnosis: ection, IV Drug Use				

LSC Lead Screening in	SC Lead Screening in Children					
Measure Definition:						
The percentage of children turning 2 years of age in the measruement year who had one or more capillary or venous lead blood test for lead poisoning by their second birthday.						
 Lead screening is of age A lead risk assess requirement for Mee Options exist for 	Common Chart Deficiencies and Tips: 1. Lead screening is considered late if performed after the child turns 2 years					
	Billing Reference					
Description	СРТ					
Lead Tests	ead Tests 83655					
HEDIS® stands for Healthcare Effectiveness Data a	EDIS® stands for Healthcare Effectiveness Data and Information Set and is a registered trademark of the National Committee for Quality Assurance (NCQA).					

MMA Medication Management for People With Asthma

Measure Definition:

The percentage of members 5–64 years of age in the measurement year who were identified as having persistent asthma and dispensed appropriate medications that they remained on during the treatment period. Two rates are reported:

1. The percentage of members who remained on an asthma controller medication for at least 50% of their treatment period.

2. The percentage of members who remained on an asthma controller medication for at least 75% of their treatment period.

	B	illing Reference				
Description	ICD-10 CM					
Asthma J45.20-J45.22, J45.30-J45.32, J45.40-J45.42, J45.50-J45.52, J45.901-J45.902, J45.909, J45.990-J45.991, J45.998						
Asthma Controller Medications						
Description		Prescri	ptions			
Antiasthmatic Combinations	Dyphylline-guaifenesin					
Antibody Inhibitor	• Omalizumab					
Anti-interleukin-5	 Mepolizumab 	Mepolizumab e Reslizumab				
Inhaled Steroid	Budesonide-form	oterol	Fluticasone-salmeterol			
Combinations	Mometasone-form	Mometasone-formoterol Fluticasone-vilanterol				
	Beclomethasone		• Flunisolide			
Inhaled Corticosteroids	Budesonide		• Fluticasone CFC free			
	Ciclesonide		Mometasone			
Leukotriene Modifiers	Montelukast	• Zafirlukast	• Zileuton			
Methylxanthines	Theophylline					
Members with any of these diagnoses, anytime in their history are excluded from this measure:						
Acute Respiratory Failure,	Chronic Respiratory	Conditions Due to Fume	es/Vapors, COPD, Cystic Fibrosis,			
Emphysema, Obstructive		• •				
-	mbers who had no as	sthma controller medica	tions dispensed during the measurement			
year.						
HEDIS [®] stands for Healthcare Effective	eness Data and Information Set	and is a registered trademark of th	e National Committee for Quality Assurance (NCQA).			

OMW Osteoporosis Management in Women Who Had a

Fracture

Measure Definition:

The percentage of women 67–85 years of age who suffered a fracture and who had either a bone mineral density (BMD) test or prescription for a drug to treat osteoporosis in the six months after the fracture.

Billing Reference								
Description		СРТ	HCPCS	ICD-10 PC	S			
Bone Mineral Density Test		77, 77078, 77080- 982, 77085-77086	G0130	BP48ZZ1, BP49ZZ1, BP4GZZ1, BP4HZZ1, BP4LZZ1, BP4MZZ1, BP4NZZ1, BP4PZZ1, BQ00ZZI, BQ01ZZ1, BQ03ZZ1, BQ04ZZ1, BR00ZZ1, BR07ZZ1, BR09ZZ1, BR0GZZ1				
		FDA-Approv	ved Osteo	oporosis Therapies				
Description	n		Prescr	iptions	HCPCS J			
		Alendronate		Risedronate				
Biphosphonates		Alendronate- cholecalciferol		Zoledronic acid	J1740, J3487, J3488, J3489, Q2051			
Ibandronate					Q2031			
		Abaloparatide		Raloxifene				
Other agents		Calcitonin		Teriparatide	J0630, J0897,			
		Denosumab			J3110			
Additional Exc	clusi	on Criteria						
Exclude from M	edica	re reporting mem	bers age 67	7 and older as of 12/31 of the	emeasurement			
year who were e during the meas			nal SNP or	living long-term in an institu	tion any time			
Exclude membe	rs ag	e 67 to 80 as of 12	2/31 of the	measurement year with BOT	H advanced			
illness and frailt	y: a	claim for an advan	ced illness	condition from the measure	ment year or the			
year prior and a	year prior and a claim for frailty in the measurement year.							
Exclude member frailty claim.	rs ag	e 81 and older as c	of 12/31 of	the measurement year who	had at least one			
UEDIC® stands for Upplthouse Effectiveness Data and lefermation Set and is a resistand trademark of the National Committee for Quality Assurance								

HEDIS[®] stands for Healthcare Effectiveness Data and Information Set and is a registered trademark of the National Committee for Quality Assurance (NCQA).

PBH Persistence of Beta-Blocker Treatment After a Heart Attack

Measure Definition:

The percentage of members 18 years of age and older in the measurement year who were hospitalized and discharged from July 1 of the year prior to the measurement year to June 30 of the measurement year with a diagnosis of AMI and who received persistent beta-blocker treatment for six months after discharge.

treatment for six months after discharge.						
Billing Reference						
Description		ICD-10 CM				
АМІ	121.01-121.02, 121.09, 121.11, 12	I21.01-I21.02, I21.09, I21.11, I21.19, I21.21, I21.29, I21.3, I21.4, I21.9, I21.A1,				
		I21.A9				
Beta-Blocker Medications						
Description	Description Prescriptions					
	Carvedilol	Propranolol				
Noncardioselective beta- blockers	Labetalol	Timolol				
	Nadolol	Sotalol				
	Pindolol					
Conditional antitude haste	Acebutolol	Bisoprolol				
Cardioselective beta- blockers	Atenolol	Metoprolol				
DIOCKEIS	Betaxolol	Nebivolol				
	Atenolol-chlorthalidone	Hydrochlorothiazide-metoprolol				
Antihypertensive combinations	Bendroflumethiazide-nadolol	Hydrochlorothiazide-propranolol				
compinations	Bisoprolol-hydrochlorothiazide					
Measure Exclusion Cri	teria:					
Patients identified as havi	ng an intolerance or allergy to be	ta-blocker therapy. Any of the following				

Patients identified as having an intolerance or allergy to beta-blocker therapy. Any of the following anytime during the member's history through 179 days after discharge:

Members with any of these diagnoses, anytime in their history are excluded from this measure:

History of Asthma, Chronic Respiratory Conditions Due to Fumes/Vapors, COPD, Obstructive Chronic Bronchitis, Hypotension, Heart Block >1st degree, Sinus bradycardia, a medication dispensing event indicative of a history of asthma.

Other Exclusions

Exclude from Medicare reporting members age 66 and older as of 12/31 of the measurement year who were enrolled in an Institutional SNP or living long-term in an institution any time during the measurement year.

Exclude members age 66 to 80 as of 12/31 of the measurement year with BOTH advanced illness and frailty: a claim for an advanced illness condition from the measurement year or the year prior and a claim for frailty in the measurement year.

Exclude members age 81 and older as of 12/31 of the measurement year who had at least one frailty claim.

HEDIS® stands for Healthcare Effectiveness Data and Information Set and is a registered trademark of the National Committee for Quality Assurance (NCQA).

PCE Pharmacotherapy Management of COPD Exacerbation

Measure Definition:

The percentage of COPD exacerbations for members 40 years of age and older who had an acute inpatient discharge or ED visit on or between January 1–November 30, 2017 and who were dispensed appropriate medications. Two rates are reported:

1. Dispensed a systemic corticosteroid (or there was evidence of an active prescription) within 14 days of the event.

2. Dispensed a bronchodilator (or there was evidence of an active prescription) within 30 days of the event.

	Billing Referenc	e					
Description		ICD-10 CM					
COPD	J4	J44.0, J44.1, J44.9					
Emphysema	J43.0)-J43.2, J43.8, J43.9					
Chronic Bronchitis	J41.	0, J41.1, J41.8, J42					
	COPD Medication	S					
	Systemic Corticoster	oids					
Description Prescriptions							
	Cortisone-acetate	Methylprednisolone					
Glucocorticosteroids	Dexamethasone	Prednisolone					
	Hydrocortisone	Prednisone					
	Bronchodilators						
Description		Prescriptions					
	Albuterol-ipratropium	Ipratropium					
Anticholinergic Agents	Aclidinium-bromide	Tiotropium					
	Umeclidinium						
	Albuterol	Indacaterol-glycopyrrolate					
	Arformoterol	Levalbuterol					
	Budesonide-formoterol	Mometasone-formoterol					
Poto 2 ogonista	Fluticasone-salmeterol	Metaproterenol					
Beta 2-agonists	Fluticasone-vilanterol	Olodaterol-hydrochloride					
	Formoterol	Olodaterol-tiotropium					
	Formoterol-glycopyrrolate	Salmeterol					
	Indacaterol	Umeclidinium-vilanterol					
Antiasthmatic combinations	Dyphylline-guaifenesin						

HEDIS® stands for Healthcare Effectiveness Data and Information Set and is a registered trademark of the National Committee for Quality Assurance (NCQA).

PPC Prenatal and Po	stpartum Care						
Measure Definition:							
The percentage of deliveries of live births between November 6, 2017 and November 5, 2018. For these women, the measure assesses the following facets of prenatal and postpartum care.							
<i>Timeliness of Prenatal Care.</i> The percentage of deliveries that received a prenatal care visit as a member of the organization in the first trimester <i>or</i> within 42 days of enrollment in the organization. <i>Postpartum Care.</i> The percentage of deliveries that had a postpartum visit on or between 21 and 56 days after delivery.							
 Common Chart Deficiencies and Tips 1. C-section suture/staple removal appointment prior to 21 days after delivery does not meet measure criteria 2. Schedule postpartum follow-up visit for C-section patients before they leave after suture/staple removal. 							
	Billing	g Refere	ence				
	Timeliness						
Codes to Identify Prenatal Care Visit - Method 1							
Description	CPT/C				HCI	PCS	
Prenatal Bundled Services	59400, 59425, 5942 596:		59610,		H10	005	
Stand Alone Prenatal Visits	99500, 0500F, (0501F, 05	02F		H1000-	-H1004	
Со	des to Identify Pre	natal Ca	re Visits	- Methoo	2		
СРТ			HC	PCS		UB Revenue	
99201-99205, 99211-9921	L5, 99241-99245		T1015,	G0463		0514	
WITH C	One of the Followin	g Diagno	osis or Pr	ocedure	Codes:		
Description	CP	Т			ICD-1	0 PCS	
Obstetric Panel	80055,8						
Prenatal Ultrasound	76801, 76805, 7681 76821, 768	• •	76815-	BY49ZZZ	, BY4BZZZ- BY40	BY4DZZZ, BY4FZZZ, GZZZ	
Pregnancy Diagnosis ICD10CM O08.0-O9A519, Z03.71-Z36.9							
		OR					
A provider visit code W	A provider visit code WITH Toxoplasma Antibody, Rubella Antibody, Cytomegalovirus, and Herpes Simplex CPT:						
Toxoplasma Antibody	86777, 86778	3	Rubella A	ntibody		86762	
Cytomegalo- virus Antibody	86644		Herpes Si Antibody	mplex	8	6694-86696	

Codes to Identify Prenatal Care Visits - Method 2 continued						
OR						
Description	CPT HCPCS UB Revenue				UB Revenue	
Provider V	Visit Code WITH Ru	ubella An	tibody a	nd ABO C	PT Code	:
Rubella Antibody	86762	AN	ID	AB	0	86900
		OR				
Pro	ovider Visit WITH R	ubella Ar	ntibody a	and Rh CF	PT:	
Description			СР	T		
Rubella Antibody	86762 AND Rh 86901					
	OR					
Provider Vis	it WITH Rubella An	ntibody a	nd ABO/	Rh CPT/L	OINC Co	de:
Description			СР	T		
Rubella Antibody CPT	86762	AND	ABO/R			-8, 882-1, 884-7
Identifying Prenatal Care Visits - Method 3 - PCP						
A visit with the PCP during the first trimester can count as a prenatal visit if:						
a pregnancy diagnosis code is submitted on the same claim as the visit AND at least one of the services						
described above in method 2 is completed on the same or different date of service						

Postpartum Visit - Any of the following Meet Criteria					
Description	CPT/CPT II		I	CD-10 CM	HCPCS
Postpartum Visit	57170, 58300, 59430, 99501, 0503F			G0101	
Description	СРТ		UB Rev	HCPCS	
Cervical Cytology	88141-88143, 88147, 88148, 88150, 88152-88154, 88164- 88167, 88174, 88175		0923	G0123, G0124, G0141, G014 G0147, G0148, P3000, P300	-
Description	СРТ				
Postpartum Bundled Services	59400, 59410, 59510, 59515, 59610, 59614, 59618, 59622				
HEDIS® stands for Healthcare Effectiveness Data and Information Set and is a registered trademark of the National Committee for Quality Assurance (NCQA).					

PSA Non-Recommended PSA-Based Screening in Older Men

Measure Definition:

The percentage of men 70 years and older who were screened unnecessarily for prostate cancer using prostate-specific antigen (PSA)-based screening.

Billing Reference				
Exclusions				
Description	ICD-10 CM			
Prostate Cancer	C61, D07.5, D40.0, Z15.03, Z85.46			
Prostate Dysplasia	N42.3-N42.32, N42.39			
Description	СРТ	HCPCS		
A PSA test during the year prior to them measurement year, where laboratory data indicate an elevated result (>4.0 ng/mL)				
Dispensed a prescription for a 5-alpha reductase inhibitor (Finasteride or Dutasteride) during the measurement year.				
IEDIS [®] stands for Healthcare Effectiveness Data and Information Set and is a registered trademark of the National Committee for Quality Assurance (NCQA).				

SAA Adherence to Antipsychotic Medications for Individuals With Schizophrenia

Measure Definition:

The percentage of members 19-64 years of age during the measurement year with schizophrenia who were dispensed and remained on antipsychotic medication for at least 80% of their treatment period.

Common Chart Deficiencies and Tips:

1. Discuss and assess for possible side effects at each visit and address if an issue.

Dilling Deference					
Billing Reference					
Diagnosis	ICD-10 CM				
Schizophrenia	F20.0-F20.3, F20.5, F20.81, F20.89, F20.9, F25.0, F25.1, F25.8, F25.9				
Exclusions	ICD-10 CM				
Dementia Dx during the measurement year	F01.50. F01.51, F02.80, F02.81, F03.90, F03.91, F04. F10.27, F10.97. F13.27, F13.97, F18.17, F18.27, F18.97, F19.17, F19.27, F19.97, G30.0, G30.1. G30.8, G30.9, G31.83,				
measurement year					
Member did not have at least	two antipsychotic m	edication dispensing	events in the meas	urement year.	
Oral Antipsychotic Medica	itions				
Description	Prescription				
	Aripiprazole	Clozapine	Lurisadone	Quetiapine	
Miscellaneous antipsychotic	Asenapine	Haloperidol	Molindone	Quetiapine fumarate	
agents (oral)	Brexpiprazole	lloperidone	Olanzapine	Risperidone	
	Cariprazine	Loxapine	Paliperidone	Ziprasidone	
Phenothiazine antipsychotics	Chlorpromazine Perphenazine Thioridazine				
(oral)	Fluphenazine	Prochlorperazine	Trifluoperazine		
Psychotherapeutic combinations (oral)	Amitriptyline-perphenazine				
Thioxanthenes (oral)	Thiothixene				
Antipsychotic Injections					
Description	Prescription				
Long acting injections 29 days	Aripiprazole		Olanzapine		
Long-acting injections 28-days	Fluphenazine decan	oate	Paliperidone palmitate		
supply	Haloperidol decano	ate			
Long-acting injections 14-days supply	Risperidone				
HEDIS [®] stands for Healthcare Effectiveness Data and Information Set and is a registered trademark of the National Committee for Quality Assurance (NCQA).					

SPC Statin Therapy for Patients with Cardiovascular Disease

Measure Definition:

The percentage of males 21-75 years of age and females 40-75 years of age during the measurement year, who were identified as having clinical atherosclerotic cardiovascular disease (ASCVD) and met the following criteria. The following rates are reported:

1. *Received Statin Therapy*. Members who were dispensed at least one high-intensity or moderate-intensity statin medication during the measurement year.

2. *Statin Adherence 80%*. Members who remained on a high-intensity or moderateintensity statin medication for at least 80% of the treatment period.

Common Chart Deficiencies and Tips:

1. Review medication list at every visit.

Diagnosis

Members are identified for this measure by event or diagnosis.

Events: Any of the following during the year prior to the measurement year:

Discharged from an inpatient setting with an MI diagnosis, CABG, PCI or other revascularization procedures. <u>Diagnosis</u>: Members identified as having ischemic vascular disease during at least one OP visit or one IP encounter, during the measurement year and the year prior to the measurement year.

Exclusions	ICD-10 CM/PCS			
ESRD	N18.5, N18.6, Z91.15, Z99.2, 3E1M39Z, 5A1D00Z, 5A1D60Z			
Cirrhosis	K70.30, K70.31, K71.7, K74.3 - K74.5, K74.60, K74.69, P78.81			
Myalgia, myopathy, myositis or rhabdomyolysis	G72.0, G72.2, G72.9, M62.82, M79.1			
Pregnancy during the measure	e year or year prior			
In vitro fertilization in the mea	asurement year or the year prior			
Dispensed a prescription for C	lomiphene during the measurement y	ear or the year prior		
Other Exclusions				
		any time during the measurement year.		
Exclude members age 66 to 8	0 as of 12/31 of the measurement yea	ar with BOTH advanced illness and frailty:		
	s condition from the measurement ye	ar or the year prior and a claim for frailty		
in the measurement year.	s condition from the measurement ye	ar or the year prior and a claim for frailty		
in the measurement year. HEDIS [®] stands for Healthcare Effectiveness Da	ta and Information Set and is a registered trademark of t	ar or the year prior and a claim for frailty		
in the measurement year. HEDIS [®] stands for Healthcare Effectiveness Da	ta and Information Set and is a registered trademark of t	ar or the year prior and a claim for frailty		
in the measurement year. HEDIS® stands for Healthcare Effectiveness Da High and Moderate-Inten	ata and Information Set and is a registered trademark of t	ar or the year prior and a claim for frailty		
in the measurement year. HEDIS® stands for Healthcare Effectiveness Da High and Moderate-Inten	ata and Information Set and is a registered trademark of t sity Statin Medications Atorvastatin 40-80 mg	ar or the year prior and a claim for frailty he National Committee for Quality Assurance (NCQA). Rosuvastatin 20-40 mg		
in the measurement year. HEDIS® stands for Healthcare Effectiveness Da High and Moderate-Inten	ata and Information Set and is a registered trademark of t sity Statin Medications Atorvastatin 40-80 mg Amlodipine-atorvastatin 40-80 mg	ar or the year prior and a claim for frailty he National Committee for Quality Assurance (NCQA). Rosuvastatin 20-40 mg		
in the measurement year. HEDIS® stands for Healthcare Effectiveness Da High and Moderate-Inten High-intensity statin therapy	ata and Information Set and is a registered trademark of t sity Statin Medications Atorvastatin 40-80 mg Amlodipine-atorvastatin 40-80 mg Ezetimibe-simvastatin 80 mg	ar or the year prior and a claim for frailty he National Committee for Quality Assurance (NCQA). Rosuvastatin 20-40 mg Simvastatin 80 mg		
in the measurement year. HEDIS® stands for Healthcare Effectiveness Da High and Moderate-Inten High-intensity statin therapy Moderate-intensity statin	ata and Information Set and is a registered trademark of t sity Statin Medications Atorvastatin 40-80 mg Amlodipine-atorvastatin 40-80 mg Ezetimibe-simvastatin 80 mg Atorvastatin 10-20 mg	ar or the year prior and a claim for frailty he National Committee for Quality Assurance (NCQA). Rosuvastatin 20-40 mg Simvastatin 80 mg Pravastatin 40-80 mg		
in the measurement year.	ata and Information Set and is a registered trademark of t sity Statin Medications Atorvastatin 40-80 mg Amlodipine-atorvastatin 40-80 mg Ezetimibe-simvastatin 80 mg Atorvastatin 10-20 mg Amlodipine-atorvastatin 10-20 mg	ar or the year prior and a claim for frailty he National Committee for Quality Assurance (NCQA). Rosuvastatin 20-40 mg Simvastatin 80 mg Pravastatin 40-80 mg Lovastatin 40 mg		

SPD Statin Therapy for Patients With Diabetes

Measure Definition:

The percentage of members 40-75 years of age during the measurement year with diabetes who do not have clinical atherosclerotic cardiovascular disease (ASCVD) who met the following criteria. Two rates are reported:

1. *Received Statin Therapy* . Members who were dispensed at least one statin medication of any intensity during the measurement year.

2. *Statin Adherence 80%*. Members who remained on statin medication of any intensity for at least 80% of the treatment period.

- Common Chart Deficiencies and Tips:
- 1. Review medication list at every visit .
- 2. Educate patients about the importance of medication compliance.

Diagnosis

Members are identified for this measure claims/encounter data and pharmacy data. The members must have at least 2 outpatient visits or 1 acute inpatient encounter with the diagnosis of diabetes in the measurement year or the year prior. Or the member was dispensed insulin or

hypoglycemics/antihyperglycemics on an ambulatory basis during the measurement year or the year prior.

Exclusion Criteria

During the year prior to the measurement year: Diagnosis of MI, CABG, PCI, other revascular procedure.

During the measurement year or year prior: Pregnancy, IVF, dispensed at least one Rx for Clomophene, ESRD or Cirrhosis.

During the measurement year: Myalgia, Myositis, Myopathy or Rhabdomyolysis.

In both the measurement year AND the year prior to the measurement year : IVD

Other Exclusions

Exclude from Medicare reporting members age 66 and older as of 12/31 of the measurement year who were enrolled in an Institutional SNP or living long-term in an institution any time during the measurement year.

Exclude members age 66 to 80 as of 12/31 of the measurement year with BOTH advanced illness and frailty: a claim for an advanced illness condition from the measurement year or the year prior and a claim for frailty in the measurement year.

HEDIS® stands for Healthcare Effectiveness Data and Information Set and is a registered trademark of the National Committee for Quality Assurance (NCQA).

Statin Medications		
High-intensity statin	Atorvastatin 40-80 mg	Rosuvastatin 20-40 mg
	Amlodipine-atorvastatin 40-80 mg	Simvastatin 80 mg
therapy	Ezetimibe-simvastatin 80 mg	
	Atorvastatin 10-20 mg	Pravastatin 40-80 mg
Moderate-intensity statin	Amlodipine-atorvastatin 10-20 mg	Lovastatin 40 mg
· · · ·	Rosuvastatin 5-10 mg	Fluvastatin XL 80 mg
therapy	Simvastatin 20-40 mg	Fluvastatin 40 mg bid
	Ezetimibe-simvastatin 20-40 mg	Pitavastatin 2–4 mg
Low-intensity statin	Simvastatin 10 mg	Lovastatin 20 mg
	Ezetimibe-simvastatin 10 mg	Fluvastatin 20–40 mg
therapy	Pravastatin 10–20 mg	Pitavastatin 1 mg

SSD Diabetes Screening for People with Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications

Measure Definition:

The percentage of members 18-64 years of age with schizophrenia, schizoaffective disorder or bipolar disorder, who were dispensed antipsychotic medication and had a diabetes screening test during the measurement year.

Common Chart Deficiencies and Tips:

1. Order a diabetes screening test every year and check every visit to ensure that it has been completed.

2. Educate patients about the importance of the test.

3. Check at each visit for the completed test and reorder if not done.

Billing Reference				
Diagnosis	ICD-10 CM			
Schizophrenia	F20.0-F20.3, F20.5, F20.81, F20.89, F20.9, F25.0, F25.1, F25.8, F25.9			
Bipolar Disorder	F30.10-F30.13, F30.2-F30.4, F30.8-F30.9, F31.0, F31.1-F31.13, F31.2- F31.32, F31.4-F31.64, F31.7-F31.78			
Test Description	CPT/CPT II Code			
Glucose Test	80047, 80048, 80050, 80053, 80069, 82947, 82950, 82951			
HbA1C Test	83036, 83037, 3044F-3046F			

Measu	re Definition:		
	The percentage of children 3 months to 18 years of age who were given a diagnosis of		
	upper respiratory infection and <u>were not</u> dispensed an antibiotic.		
	*Inverted Measure: Numerator identifies members who received an		
	antibiotic; considered non-compliant for the intent of this measure.		
	Billing Reference		
	ICD-10-CM URI Diagnosis		
	J00, J06.0, J06.9		
	ICD-10 CM Pharyngitis Diagnosis		
	J02.0, J02.8-J03.01, J03.80-J03.81, J03.90-J03.91		
Meas	sure Exclusion Criteria:		
	The member is excluded from the measure if he/she has a diagnosis of pharyngitis or		
	another competing diagnosis 30 days prior to or 7 days after the acute bronchitis		
	diagnosis. The list of competing diagnosis includes all types of infections that would		
	require treatment with an antibiotic.		

W15 Well-Child Visits in the First 15 Months of Life Measure Definition: The percentage of members who turned 15 months old in the measurement year and had the following number of well-child visits with a PCP during their first 15 months of life: No well-child visits Four well-child visits

No well-child visits One well-child visit Two well-child visits Three well-child visits Four well-child visits Five well-child visits Six well-child visits (goal)

The comprehensive well care visit includes:

- Health history assessment of history of disease or illness and family health history
- Physical developmental history assessment of specific age appropriate physical development milestones
- Mental development history assessment of specific age appropriate mental development milestones
- Physical exam
- Health education/anticipatory guidance guideance given in anticipation of emerging issues that a child/family may face

Common Chart Deficiencies and Tips:

- 1. Missing or undocumented anticipatory guidance
- 2. Sick visit in calendar year without well-child visit -turn a sick visit into
- a well-child visit
- 3. Schedule next visit at the end of each appointment
- 4. Call parent/guardian to reschedule when a visit is missed
- 5. Educate parent/guardian regarding the need for so many visits during

Billing Reference				
Description	СРТ	HCPCS	ICD-10 CM	
Office Visit	99381-99382, 99391 99392, 99461	G0438, G0439	Z00.11-Z00.129, Z00.5, Z00.8, Z02.0-Z02.9	
HEDIS [®] stands for Healthcare Effectiveness Data and Information Set and is a registered trademark of the National Committee for Quality Assurance (NCQA).				

W34 Well-C Life	hild Visits in th	e Third, Fou	urth, Fifth, and Sixth Years of			
Measure Definitio	Measure Definition:					
The percentage of members 3–6 years of age who had one or more well-child visits with a PCP in 2017.						
The comprehensive well care visit includes:						
• H	ealth history - assessn	nent of history of	disease or illness and family health history			
 Health history - assessment of history of disease or illness and family health history Physical developmental history - assessment of specific age appropriate physical development milestones Mental development history - assessment of specific age appropriate mental development milestones Physical exam Health education/anticipatory guidance - guideance given in anticipation of emerging issues that a child/family may face Common Chart Deficiencies and Tips: Missing or undocumented anticipatory guidance Sick visit in calendar year without well-child visit -turn a sick visit into a well-child visit Schedule next visit at end of each appointment Call parent/guardian to reschedule when a visit is missed 						
	I	Billing Refere	nce			
Description	СРТ	HCPCS	ICD-10 CM			
Office Visit	99382-99383, 99392- 99393	G0438, G0439	Z00.121-Z00.129, Z00.5, Z00.8, Z02.0-Z02.9			
IEDIS [®] stands for Healthcare Effectiveness Data and Information Set and is a registered trademark of the National Committee for Quality Assurance NCQA).						

WCC Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents

Measure Definition:

The percentage of members 3–17 years of age who had an outpatient visit with a PCP or OB/GYN and who had BMI percentile documentation, counseling for nutrition, and counseling for physical activity during the measurement year.

Common Chart Deficiencies and Tips:

1. BMI percentile or BMI percentile plotted on growth chart for members 3-17 years of age required to meet measure. BMI value alone does NOT meet compliance

2. Must include documentation indicating counseling for nutrition and

Billing Reference					
Description	СРТ	HCPCS	ICD-10 CM		
BMI Percentile			Z68.51-Z68.54		
Nutrition Counseling	97802-97804	G0270, G0271, G0447, S9449, S9452, S9470	Z71.3		
Physical Activity Counseling		G0447 (face to face behavioral counseling for obesity—15 minutes) , S9451 (Exercise classes— non-physician provider)	Z02.5 (Sports physical) Z71.82 (<u>Exercise counseling)</u>		
Measure Exclusion Criteria:					
Any diagnosis of pregnancy during the measurement year counts as an exclusion for this					
measure					
HEDIS [®] stands for Healthcare Effectiveness Data and Information Set and is a registered trademark of the National Committee for Quality Assurance (NCQA).					